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Abstract To assess the combination effect of calcitonin and
the phosphodiesterase 4 inhibitor rolipram on osteo-
clastogenesis, adherent cell-depleted bone marrow cells
from mouse tibia and femur (ACD-BMCs), which were
cultured in the presence of 25ng/ml colony-stimulating fac-
tor 1 (CSF-1) and 100ng/ml soluble receptor activator of
NF-κB ligand (sRANKL), were utilized. Calcitonin inhib-
ited formation of tartrate-resistant acid phosphatase-
positive multinucleated cells, as mature osteoclasts, by 70%
even at 20pM, whereas rolipram (10µM) scarcely affected
osteoclast formation; in contrast, the combination of both
agents led to significant inhibition of multinucleation and
pit formation ability of osteoclasts. The combined adminis-
tration of calcitonin and rolipram attenuated calcitonin re-
ceptor mRNA expression in comparison to treatment with
either agent alone, whereas expression of RANK and CSF-
1 receptor mRNAs was unchanged. Alone, these agents
scarcely elevated intracellular cyclic AMP (cAMP) concen-
tration; however, combination treatment with both agents
significantly increased cAMP concentration in osteoclast
progenitors and osteoclasts. The combination effect was
abolished by H-89, an inhibitor of protein kinase A. It
appears that rolipram inhibited hydrolysis of cAMP formed
by calcitonin in cells and potentiated the inhibitory effect
of calcitonin on osteoclastogenesis. The escape phenom-
enon following calcitonin treatment may also be prevented
by concomitant treatment with the phosphodiesterase 4
inhibitor.
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Introduction
The signal pathways of parathyroid hormone and calcitonin
(CT), which regulate calcium metabolism, involve cyclic
AMP (cAMP) as an intracellular second messenger follow-
ing stimulation of the receptors on osteoblasts and osteo-
clasts, respectively [1]. Therefore, inhibition of hydrolysis of
cAMP produced in response to these hormones is expected
to potentiate the action of these hormones on bone cells.
Cyclic nucleotide phosphodiesterase (PDE) is classified
into 11 isoenzyme families, which differ in their substrate
specificity, affinity for cyclic nucleotides, and regulatory
properties [2–5]. Among these families, PDE 4 isoenzyme is
a cAMP-specific PDE; furthermore, its inhibitors display
selective bronchodilator activity [6,7] and antiinflammatory
action [8]. Moreover, we recently reported that among PDE
inhibitors the PDE 4 inhibitor specifically increased osteo-
blast formation and decreased osteoclast formation in in
vitro bone marrow culture; additionally, we identified a
therapeutic effect of PDE 4 inhibitors against bone loss in
some animal osteopenia models [9,10]. We also indicated
that the effects of PDE 4 inhibitors on osteoblast and osteo-
clast formation synergistically inhibit hydrolysis of cAMP in
the progenitor cells produced by prostaglandin E2 (PGE2)
secreted by bone marrow stromal cells [11,12].
Osteoclast progenitor cells are stimulated and their
maturation is promoted via membrane interaction with
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osteoblasts/stromal cells through the receptor activator of
nuclear factor κB (RANK), which is a receptor activator
of the nuclear factor κB ligand (RANKL) system [13,14].
Osteoclast formation and maturation are promoted by
a production ratio of RANKL versus osteoprotegerin
(OPG; a decoy receptor for RANKL secreted by stromal
cells; also referred to as osteoclastogenesis inhibitory factor,
OCIF) following stimulation of osteoblastic stromal cells
by osteotropic factors such as 1α,25-dihydroxyvitamin
D3 (1,25(OH)2D3), para thyroid hormone (PTH), or
interleukin 11 (IL-11) [15,16]. Therefore, osteoclasto-
genesis is regulated by interaction with stromal cells and
stimulation involving several osteotropic factors. On the
other hand, it is well known that CT directly inhibits osteo-
clast formation and its bone resorption activity [17–19].
This study examined the direct effect of CT on
osteoclastogenesis and the combination effect of the PDE 4
inhibitor rolipram employing adherent cell-depleted bone
marrow cells from mouse tibia and femur (ACD-BMCs),
which were cultured in the presence of 25ng/ml colony-




Rolipram (Wako, Osaka, Japan), naphthol AS-MX
phosphate sodium, fast red violet LB salt (Sigma, St.
Louis, MO, USA), salmon calcitonin (CT; Bachem
Feinchemikalien, Bubendorf, Switzerland), and N-[2-(p-
bromocinnamylamino)ethyl]-5-isoquinoline-sulfonamide
(H-89; Seikagaku Kogyo, Tokyo, Japan) were purchased
from the respective commercial sources. Recombinant
human CSF-1 and recombinant human sRANKL were
acquired from PeproTech (London, England). Male ddY
mice (8 weeks of age; Nippon SLC, Hamamatsu, Japan)
were used randomly in this study.
Preparation of ACD-BMCs
Suspensions (2ml) of bone marrow cells obtained from
mouse tibiae and femurs were gently introduced into the
Sephadex G-10 (Amersham Pharmacia Biotech, Bucks,
U.K.) column system according to the method of Ly and
Mishell [20]. Cells were infiltrated with the carrier; subse-
quently, the cell suspension was introduced to 8ml of the
medium, followed by incubation at 37°C for 45min. Next,
the eluted suspension of nonadherent bone marrow cells
was collected and used as ACD-BMCs.
Primary culture of ACD-BMCs
According to a method described by Niida et al. [21], ACD-
BMCs were cultured to generate osteoclasts. Wells of 96-
well plates were coated with 5µl of a solution containing
625ng/ml CSF-1 and 2.5µg/ml sRANKL in fetal bovine
serum (FBS) and dried for 1h on a clean bench. The ACD-
BMCs were prepared for 1.5 × 106 cells/ml with alpha-
minimum essential medium (α-MEM) (pH 7.0) containing
15% FBS; subsequently, cell suspensions (125µl/well) were
seeded into 96-well plates. At 3 days after culture, the
medium was changed to α-MEM containing 15% FBS,
25ng/ml CSF-1, and 100ng/ml sRANKL in the presence or
absence of calcitonin and rolipram. The treatment was
conducted for 2 days, after which cultures were fixed and
stained in 0.1mg/ml naphthol AS-MX phosphate sodium,
0.6mg/ml fast red violet LB salt, and 50mM sodium tar-
trate/0.1M sodium acetate (pH 5.0) for tartrate-resistant
acid phosphatase (TRAP). Samples were washed with dis-
tilled water, dried, and observed under a light microscope.
Those cells positive for TRAP and exhibiting more than
three nuclei were counted as mature ostoclasts.
The absence of stromal cells or osteoblast progenitors in
the cell population was confirmed from bone-type alkaline
phosphatase (ALP) mRNA expression. Moreover, ALP-
positive cells or nodules were never observed as a result of
treatment with or without rolipram under these conditions,
whereas PDE 4 inhibitors, including rolipram, exerted an
osteoblastogenic action on stromal or bone marrow cells
[9–11].
Pit assay
ACD-BMCs were plated on dentine slices and cultured
in α-MEM containing 15% FBS, 25ng/ml CSF-1, and
100ng/ml sRANKL for 6 days [22]. Further incubation con-
sisted of 48-h treatment of cells on the slices in the presence
or absence of calcitonin and rolipram. After culture, the
slices were treated with 0.05M ammonium hydroxide for
30min, and cells were removed from the dentine slices.
Backscattered electron images of the dentine slices were
examined with a Hitachi S-2500CX scanning electron
microscope [23].
Reverse transcription-polymerase chain reaction assay
mRNAs were prepared from cultures utilizing a QuickPrep
micro mRNA purification kit (Pharmacia Biotech, Uppsala,
Sweden). Synthesis of cDNA from isolated mRNA was
conducted with RNase H-reverse transcriptase and ana-
lyzed for expression of mouse RANK, CSF-1 receptor
(CSF-1R), and calcitonin receptor (CT-R) transcripts by
reverse transcription-polymerase chain reaction (RT-PCR).
RT-PCR was performed using primers per details described
previously for β-actin [24]. Primers for mouse RANK were
5′-GCTTGCTGCATAAAGTCTG-T-3′ and 5′-ACGT
CCTAGAATCTCTGACT-3′ (708bp); primers for mouse
CSF-1 receptor were 5′-AACAAGTTCTACAAACTGGT
GAAGG-3′ and 5′-GAAGCCTGTAGTCTAAGCATC
TGTC-3′ (752bp); primers for mouse calcitonin receptor
were 5′-AGAATTCCTGCATCCACCTA-3′ and 5′-
TGAAAGCGTTGCACAGAGTA-3′ (558bp) (cited from




as reported by Waki et al. [24].
Measurement of cyclic AMP
Intracellular cyclic AMP (cAMP) was measured with a
cAMP EIA system (Amersham International, Little
Chalfont, U.K.).
Data analysis
Data were analyzed using Student’s t test to compare the
unpaired means of two sets of data. A P value of 0.05
indicated a significant difference between sets of data.
Results
Effect on osteoclast formation in culture of ACD-BMCs
ACD-BMCs were treated with CT (2–20pM) and/or
rolipram (10µM) in the presence of 25ng/ml CSF-1
and 100ng/ml sRANKL; subsequently, the number of
TRAP-positive MNCs was counted. As shown in Fig. 1, CT
reduced the number of TRAP-positive MNCs by approxi-
mately 70% even at 20pM; furthermore, rolipram (10µM)
alone also inhibited MNC formation somewhat. However,
rolipram synergistically potentiated the inhibitory effect of
CT on osteoclast formation. Figure 1 also exhibits abolition
of the combination effect by an inhibitor of protein kinase
A, H-89 (10µM).
Following combined treatment with CT (10pM) and
rolipram (10µM), DNA content in the culture was un-
changed (data not shown). In addition, numerous TRAP-
positive mononuclear cells were present in the culture,
although TRAP-positive MNCs were observed after CT
administration alone (Fig. 2).
Figure 3 illustrates the pit formation ability of osteoclasts
after treatment with CT (10pM) and rolipram (10µM).
Many lacunae were formed on the dentine slice of un-
treated controls and on samples treated with calcitonin
alone; in contrast, combination treatment involving CT and
rolipram abolished both osteoclast formation and lacunae
resorption.
Fig. 2. Phase-contrast micro-
graphs of ACD-BMC cultures.
Cells were cultured with 10pM
CT with (left) or without (right)
10µM rolipram under osteoclas-
togenesis conditions. After cul-
ture for 5 days, cells were fixed
and stained for TRAP
Fig. 1. Effect of rolipram on formation of tartrate-resistant acid phos-
phatase (TRAP)-positive multinucleated cells (MNCs) in adherent
cell-depleted bone marrow cells (ACD-BMCs). Cells were cultured
with 25ng/ml colony-stimulating factor 1 (CSF-1) and 100 ng/ml soluble
receptor activator of NF-κB ligand (sRANKL) (osteoclastogenesis
conditions) for 5 days and the indicated concentrations of calcitonin
(CT) in the absence or presence of 10µM rolipram and/or 10 µM H-89
for the final 2 days. After culture, cells were fixed and stained for
TRAP. , CT alone; , CT plus rolipram; H17009, CT plus rolipram plus H-
89. Each value is the mean ± SD of six experiments. *,**Significantly
different from the CT-only cultures at P < 0.05 and 0.01, respectively
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Analysis of mRNA expression
mRNAs of RANK and CSF-1R in ACD-BMCs were ex-
pressed from the early stage of culture with sRANKL and
CSF-1; however, expression of CT-R mRNA increased with
the culture period and maturation of osteoclasts [12]. CT
(10pM) slightly inhibited expression of CT-R mRNA, but
not that of RANK and CSF-1R mRNAs; furthermore, ex-
pression of CT-R mRNA was markedly decreased upon
combination with rolipram (10µM), which scarcely altered
the expression of these mRNAs alone (Fig. 4).
Effect on intracellular cAMP concentration in osteoclasts
CT (10pM) and/or rolipram (10µM) were introduced to
osteoclasts, and intracellular cAMP concentration was
measured for 1h. Figure 5 demonstrates that intracellular
cAMP concentration was little changed following addition
of CT or rolipram alone; in contrast, cAMP levels increased
significantly following combined treatment with CT and
rolipram.
Fig. 3. Scanning electron micro-
graphs of dentine slice cultured
with ACD-BMCs. ACD-BMCs
were cultured on a dentine slice
with 25ng/ml CSF-1, 100 ng/ml
sRANKL, and 10pM CT with
(left) or without (right) 10µM
rolipram. Backscattered electron
images of dentine slices are
presented
Fig. 4. mRNA expression of several factors for osteoclast differen-
tiation in ACD-BMCs. ACD-BMCs were cultured for 5 days in
the absence or presence of 10µM rolipram and/or 10pM CT under
osteoclastogenesis conditions; subsequently, expression of RANK,
CSF-1 receptor (CSF-1R), CT receptor (CT-R), and β-actin mRNAs
was analyzed via reverse transcription-polymerase chain reaction (RT-
PCR). These experiments were conducted four times; standard results
are represented
Fig. 5. Effect of rolipram and CT on intracellular cyclic AMP (cAMP)
production in ACD-BMCs. After culture for 3 days under
osteoclastogenesis conditions, cells were treated with 10µM rolipram
and/or 10 pM CT, and the concentration of intracellular cAMP was
determined after 1 h. Each value is the mean ± SD of six experiments.
**Significantly different from the control at P < 0.01
264
Discussion
When ACD-BMCs were cultured in the presence of
25ng/ml CSF-1 and 100ng/ml sRANKL for 5 days to ma-
ture osteoclasts, the inhibitory effects of CT on osteoclast
multinucleation and pit formation were synergistically po-
tentiated by combination with the PDE 4 inhibitor rolipram
(see Figs. 1–3). We previously reported that expression of
PDE 4 isoenzyme among some PDE isoenzymes increased
during culture of rat BMCs [11] and that the PDE 4
inhibitors enhanced osteoblastogenesis and diminished
osteoclastogenesis, resulting in a therapeutic effect against
bone loss in some animal osteopenia models [9,10]. Fur-
thermore, we indicated that PDE 4 inhibitors promote
osteoblast formation and inhibit osteoclast formation via
enhancement of the action of cAMP in their progenitor
cells produced by endogenous prostaglandin E2 (PGE2)
[11,12]. Thus, the PGE2 receptors are expressed on the
plasma membrane of both osteoblasts and osteoclasts, but
the signal pathways of parathyroid hormone and CT involve
cAMP as an intracellular second messenger after stimula-
tion of their receptors on osteoblasts and osteoclasts, re-
spectively [1]. Therefore, PDE 4 inhibitors may exert a
complex influence on bone metabolism in vivo.
This investigation confirmed that the PDE 4 inhibitor
rolipram potentiates the inhibitory effect of CT on
osteoclastogenesis through cAMP production in osteoclast
progenitors. It has been reported that CT immobilizes and
contracts osteoclasts away from the bone surface through
the action of cAMP enhanced because of stimulation of CT-
R [25]; however, osteoclasts continuously exposed to CT
can escape the effects of CT as a result of rapid profound
reduction in CT-R mRNA expression [26]. In this study,
following 5-day CT exposure, its effect appeared to be weak
(see Figs. 1, 3); however, it inhibited the expression of CT-
R mRNA but not that of RANK or of CSF-1R mRNAs (see
Fig. 4). These results may indicate the escape phenomena of
osteoclasts from CT. On the other hand, in combination
with rolipram, the number, particularly in the case of multi-
nuclear cells, and the function of osteoclasts were signifi-
cantly attenuated; additionally, CT-R expression decreased
further. These findings suggest that addition of a PDE 4
inhibitor during CT treatment prevents the escape phenom-
ena with respect to CT and inhibits osteoclastogenesis
through the action of elevated cAMP in osteoclast
progenitors.
Recently, several PDE 4 inhibitors have been developed
for asthma and chronic obstructive pulmonary disease and
have proceeded to late-phase clinical trial [27], although
rolipram cannot be used because of its severe side effects,
such as emesis [28]. Therefore, novel PDE 4 inhibitor drugs
may be candidates for osteoporosis therapy consequent to
their anabolic actions and potentiation of CT action.
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